Iscador*P for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Feb 2023: Trial registered, NCT05726383
  2. 14 May 2024: Trial started, NCT05726383

The trials

NCT05726383: Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma

State
Under way
Phase
Phase 2
People
32 planned
Started
14 May 2024
Primary completion
31 Dec 2028
Arms
Treatment Arm - Iscador*P
Results
None posted
  1. 13 Feb 2023: Trial registered
  2. 14 May 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.